Arcus Biosciences, Inc. (RCUS) Q4 FY25 Earnings Call

CAS monotherapy reached 45% ORR and 15.1-month median PFS at the 100-mg dose [25][27].

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-03
Length66 minutes
EPS$-0.89
EPS consensus$-1.11
Revenue$26.0M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All RCUS earnings ยท Back to RCUS overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.